Adherence to Oral Therapies in Advanced Breast and Prostate Cancers
Adherence to Oral Therapies in Advanced Breast and Prostate Cancers: a Pilot Study
Institut de Cancérologie de Lorraine
200 participants
Jun 4, 2024
INTERVENTIONAL
Conditions
Summary
AdOTAC is a pilot study, open, prospective, single-center, one-arm. The 200 patients will be included. Patient is included at Day 0. The included patient will have the opportunity to complete the self-questionnaires either at the ICL on Day 0, or at home up to 10 days after the date of inclusion in the study. Blood samples are collected the day of enrolment (Day 0) in order to measure the following biological markers: ferritin, serum iron, TSAT, albumin, and haemoglobin, except if performed as part of routine care in the previous 6 weeks.
Eligibility
Inclusion Criteria6
- Adult over 18 years old.
- Patient with inoperable advanced breast cancer treated with oral endocrine therapy and/or targeted therapy and patient with inoperable advanced prostate cancer treated with oral hormonal therapy and/or targeted therapy.
- Oral anticancer medications started for at least 3 months.
- With a performance status ≤ 3.
- Patient has understood, signed and dated the consent form.
- Patient covered by the social security system.
Exclusion Criteria8
- Patient with early breast cancer or localized prostate cancer.
- Patient with life expectancy \< 3 months.
- Patient in progression
- Undergoing intravenous or oral cytotoxic chemotherapy (capecitabine, cyclophosphamide, vinorelbine).
- Patient who has not yet started oral anticancer therapies or who has started for less than 3 months.
- Patient unable to read or speak French.
- Patient already included in another therapeutic trial with an experimental molecule.
- Persons deprived of their liberty or under guardianship (including curatorship).
Interventions
Ferritin, Transferrin Saturation (TSAT), Serum iron, Haemoglobin, Albumin
GIRERD questionnaire, AdOT questionnaire, Use of social networks and alternatives and complementary medicines using patient questionnaire, EORTC QLQC30, HADS, MNA, MSPSS
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06435546